Responsrater var stærkt i favør af de paclitaxel- indeholdende arme [13%, 30% og 26% for henholdsvis etoposid/ cisplatin, højdosis paclitaxel (p < 0. 001 vs etoposid/ cisplatin) og lavdosis paclitaxelregimer (p=0. 003 vs etoposid/ cisplatin)].
Response rates strongly favoured the paclitaxel-containing arms [13%, 30% and 26% for the etoposide/ cisplatin, high-dose paclitaxel (p < 0.001 vs etoposide/ cisplatin) and low-dose paclitaxel regimens (p= 0.003 vs